This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Talk:Semax: Difference between revisions
>Doggeaux addition of some chemistry information |
>Doggeaux m approval header |
||
| Line 1: | Line 1: | ||
{{headerpanel|{{approval}}}} | |||
{{SubstanceBox/Semax}} | {{SubstanceBox/Semax}} | ||
'''Semax''' (natively labeled '''Семакс''') is a Russian pharmaceutical [[Peptide|neuropeptide]] developed in the 1980s and approved for clinical use in 1996 after a 14-year-long testing period<ref>http://www.semaxint.com/history.htm</ref>. While commonly prescribed in Russia, Ukraine, and other [https://en.wikipedia.org/wiki/Commonwealth_of_Independent_States CIS] nations for a wide range of conditions including stroke/ischemic brain injury, Alzheimer's, depression, generalized anxiety, peptic ulcer disease, and weakened immune system, it has gained limited recognition elsewhere as a [[nootropic]] due to its mildly [[Stimulants|stimulating]] and [[Anxiety suppression|anxiolytic]] effects, neuroprotective properties, and limited side effect profile. | '''Semax''' (natively labeled '''Семакс''') is a Russian pharmaceutical [[Peptide|neuropeptide]] developed in the 1980s and approved for clinical use in 1996 after a 14-year-long testing period<ref>http://www.semaxint.com/history.htm</ref>. While commonly prescribed in Russia, Ukraine, and other [https://en.wikipedia.org/wiki/Commonwealth_of_Independent_States CIS] nations for a wide range of conditions including stroke/ischemic brain injury, Alzheimer's, depression, generalized anxiety, peptic ulcer disease, and weakened immune system, it has gained limited recognition elsewhere as a [[nootropic]] due to its mildly [[Stimulants|stimulating]] and [[Anxiety suppression|anxiolytic]] effects, neuroprotective properties, and limited side effect profile. | ||